Going Commercial, Part II
Is the FIPCO Dead? Slow Starters May Burn Bright
By Trista Morrison
Monday, May 30, 2011
Despite the fact that recent biotech product launches have fallen short of analyst expectations across the board, there's reason to believe these drugs might yet achieve their peak sales potential and foster a new wave of fully integrated pharmaceutical companies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.